Related Experiment Video

Updated: Apr 19, 2026

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

3.5K

The concurrent burden of Alzheimer's pathology, cerebral amyloid angiopathy, and microinfarcts on cognitive decline

Mingyao You1, Chao Tang1, Lianfei Liu1

  • 1Department of Neurology, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou Province 550000, China.

The Journal of Prevention of Alzheimer'S Disease
|April 17, 2026
PubMed

Insights

Vascular issues like cerebral amyloid angiopathy (CAA) and microinfarcts worsen Alzheimer's disease (AD) cognitive decline, especially in APOE ε4 carriers. A "Triple Hit" of AD, CAA, and microvascular injury significantly impairs cognition.

Area of Science:

  • Neurology
  • Pathology
  • Genetics

Background:

  • Alzheimer's disease (AD) often co-occurs with vascular conditions, but the interaction mechanisms accelerating cognitive decline are unclear.
  • Investigating the interplay between cerebral amyloid angiopathy (CAA), microinfarcts, and genetic factors in AD progression is crucial.

Purpose of the Study:

  • To determine if CAA and cortical microinfarcts mediate AD pathology's effect on cognition.
  • To evaluate how APOE genotype modifies the relationship between vascular pathology and cognitive decline in AD.

Main Methods:

  • Retrospective clinico-pathological study using the National Alzheimer's Coordinating Center (NACC) database.
  • Structural Equation Modeling (SEM) to analyze pathways from AD pathology to vascular lesions and cognitive performance.
  • Comparison of "Pure AD" cases versus "Triple Hit" (AD, CAA, microvascular injury) cases.

Main Results:

  • A significant mediation pathway was found: parenchymal amyloid strongly associates with CAA, increasing microinfarct risk and cognitive dysfunction.
  • APOE ε4 carriers showed a steeper cognitive decline with increasing CAA severity compared to non-carriers.
  • The "Triple Hit" group exhibited significantly worse cognitive impairment than the "Pure AD" group, independent of age and education.

Conclusions:

  • Vascular pathology critically mediates cognitive decline in AD, particularly in APOE ε4 carriers.
  • The combined "Triple Hit" of proteinopathy and vasculopathy severely impacts cognitive reserve, indicating a more advanced disease state.
  • Targeting vascular resilience is essential for developing disease-modifying strategies for Alzheimer's disease.
Abstract

Keywords:
APOE ε 4Alzheimer’s diseaseCerebral amyloid angiopathyCognitive declineCortical microinfarctsNeuropathology

More Related Videos

Using Retinal Imaging to Study Dementia09:17

Using Retinal Imaging to Study Dementia

Published on: November 6, 2017

22.5K
Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly12:50

Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly

Published on: April 14, 2014

41.1K

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
1
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
2
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
1
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
734
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K